3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
27
Lymphoma
25
Precursor Cell Lymphoblastic Leukemia-Lymphoma
22
Lymphoma, Non-Hodgkin
21
Leukemia
21
Multiple Myeloma
18
Leukemia, Myeloid, Acute
18
Lymphoma, Large B-Cell, Diffuse
17
Hodgkin Disease
16
Myelodysplastic Syndromes
15
Lymphoma, Mantle-Cell
15
Lymphoma, Follicular
15
Leukemia, Lymphocytic, Chronic, B-Cell
14
Congenital Abnormalities
12
Lymphoma, B-Cell, Marginal Zone
11
Burkitt Lymphoma
11
Primary Myelofibrosis
10
Myeloproliferative Disorders
10
Lymphoma, Large-Cell, Immunoblastic
10
Lymphoma, T-Cell, Cutaneous
9
Leukemia, Myeloid, Chronic-Phase
9
Leukemia, Myeloid, Accelerated Phase
9
Neoplasms, Plasma Cell
8
Dendritic Cell Sarcoma, Interdigitating
8
Blast Crisis
8
Recurrence
7
Sezary Syndrome
6
Myelodysplastic-Myeloproliferative Diseases
6
Mycosis Fungoides
6
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
6
Interventions
fludarabine phosphate
1
fludarabine
1
Mesna
1
Cyclophosphamide
1
Busulfan
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Thalassemia
×
Cyclophosphamide
×
Clear all
NCT00578292
2020-05-01
THALLO
Baylor College of Medicine
Phase NA
Terminated
10 enrolled
15 charts